Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial comparing its medication,